Hormonal

GCGR-based multi-agonists (mazdutide, pemvidutide, survodutide, retatrutide) produce significantly greater weight loss than existing GLP-1 or GLP-1/GIP therapies by synergistically combining appetite suppression with increased energy expenditure.

If you have obesity and struggle with weight loss despite lifestyle changes, GCGR-based multi-agonists (like mazdutide, retatrutide, etc.) are emerging as highly effective treatments. They work by targeting multiple hormonal pathways to suppress appetite and increase energy expenditure, often resulting in greater weight loss than current GLP-1 drugs. While they are injectable and can cause GI side effects, starting with lower doses and titrating up can help manage these effects. Consult a healthcare provider to see if you are a candidate, especially if you have comorbidities like T2DM or CV disease.